[Herpes simplex infections].
In spite of modern, highly effective antiviral drugs, the treatment of herpes simplex infections is still unsatisfactory. Especially recurrent infections as well as the protection of immunocompromised patients remain little solved therapeutical problems. Neither is the vaccination of herpes simplex promising; this has been shown in a multicenter study on a new herpes simplex virus envelope antigen vaccine. Future genotechnical investigations might provide new vaccines, which might become significant for a prophylactic therapy of herpes simplex.
Kimmig
W
W
Universitäts-Hautklinik und Poliklinik Hamburg.
D000998:Antiviral Agents / Q000627:therapeutic use*; D006561:Herpes Simplex / Q000628:therapy*; D006801:Humans; D009894:Opportunistic Infections / Q000628:therapy*; D018139:Simplexvirus / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage*; D014765:Viral Vaccines / Q000008:administration & dosage*
D000998:Antiviral Agents; D014613:Vaccines, Attenuated; D014765:Viral Vaccines
Herpes-simplex-Infektionen.